Get the Stockscreener App
9.89
0.40%
-0.04
After Hours:
9.69
-0.20
-2.02%
Fennec Pharmaceuticals Inc stock is traded at $9.89, with a volume of 134.40K.
It is down -0.40% in the last 24 hours and up +44.59% over the past month.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
See More
Previous Close:
$9.93
Open:
$9.97
24h Volume:
134.40K
Relative Volume:
0.61
Market Cap:
$343.55M
Revenue:
$44.64M
Net Income/Loss:
$-10.10M
P/E Ratio:
-28.75
EPS:
-0.344
Net Cash Flow:
$-14.45M
1W Performance:
+1.33%
1M Performance:
+44.59%
6M Performance:
+25.35%
1Y Performance:
+25.67%
1-Day Range:
$9.66
$9.98
1-Week Range:
$9.5301
$10.45
52-Week Range:
$5.65
$10.45
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Name
Fennec Pharmaceuticals Inc
Sector
Industry
Phone
(919) 636-4530
Address
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
9.89 | 344.94M | 44.64M | -10.10M | -14.45M | -0.344 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Initiated | B. Riley Securities | Buy |
| Jan-09-26 | Initiated | Piper Sandler | Overweight |
| Nov-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Aug-08-22 | Resumed | Craig Hallum | Buy |
| Jun-05-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-11-18 | Initiated | Goldman | Buy |
View All
Fennec Pharmaceuticals Inc Stock (FENC) Latest News
Fennec Pharmaceuticals Drives PEDMARK Sales as Q1 Revenue Hits Peak - HarianBasis.co
Adherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record Quarter - Yahoo Finance
H.C. Wainwright raises Fennec Pharmaceuticals stock price target on growing adoption By Investing.com - Investing.com Australia
Fennec Showcases New PEDMARK Data at ASCO 2026 - TipRanks
New PEDMARK studies at 2026 ASCO showcased by Fennec (NASDAQ: FENC) - Stock Titan
Maxim Group Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating, Maintains Target Price $15 - Moomoo
H.C. Wainwright raises Fennec Pharmaceuticals stock price target on growing adoption - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Fennec Announces New Research Supporting Pedmark's Use at ASCO Annual Meeting - Moomoo
H.C. Wainwright Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating, Raises Target Price to $16 - Moomoo
Fennec Pharmaceuticals Announced New Research Supporting Integration and Use of PEDMARK at 2026 ASCO Annual Meeting - Moomoo
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting - The Manila Times
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of Pedmark - marketscreener.com
New cancer studies test PEDMARK to protect patients’ hearing - Stock Titan
(FENC) Volatility Zones as Tactical Triggers - Stock Traders Daily
Fennec Pharmaceuticals Grants Inducement Stock Options to New Employees Under Nasdaq Rule and Highlights PEDMARK®/PEDMARQSI® Commercialization Progress 1 - Minichart
(FRX) Strategic Market Analysis (FRX:CA) - Stock Traders Daily
Fennec (NASDAQ: FENC) issues 50,000 inducement stock options to new hires - Stock Titan
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fennec Pharmaceuticals Inc.Common Stock (NQ: FENC - FinancialContent
Fennec Pharmaceuticals : Corporate Presentation May 2026 - marketscreener.com
Three new Fennec hires get options on 50,000 shares at $9.75 - Stock Titan
Fennec Pharmaceuticals Inc Company Profile & Introduction - Moomoo
Fennec Pharmaceuticals(FENC) Stock Options Chain | Quotes & News - Moomoo
Fennec Pharmaceuticals (FENC) Stock Forum and Discussion - Moomoo
[SCHEDULE 13G/A] FENNEC PHARMACEUTICALS INC. Amended Passive Investment Disclosure - Stock Titan
Piper Sandler Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Fennec Pharmaceuticals (NASDAQ:FENC) Is In A Strong Position To Grow Its Business - Moomoo
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q1 2026 Earnings Call Transcript - Insider Monkey
Fennec Pharmaceuticals Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Fennec Pharmaceuticals (NASDAQ: FENC) turns Q1 profit as PEDMARK sales climb - Stock Titan
Rosalind group files Schedule 13G/A reporting stakes in Fennec (FENC) - Stock Titan
Adherex Technologies Q1 Earnings Call Highlights - TradingView
Earnings call transcript: Fennec Pharmaceuticals Q1 2026 earnings beat expectations By Investing.com - Investing.com Nigeria
Fennec Pharmaceuticals Crushes Q1 2026 Profit Estimates by 200.0% - AlphaStreet
Earnings call transcript: Fennec Pharmaceuticals Q1 2026 earnings beat expectations - Investing.com
Fennec Pharmaceuticals announces first quarter earnings and strategic initiatives - Traders Union
Fennec Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Fennec Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Fennec Pharmaceuticals Shares Rise After Earnings and Revenue Beat Forecasts (FENC) - Yahoo Finance
Fennec Pharmaceuticals up 12.6% in U.S. Pre-Market on Q1 Earnings as Pedmark Sales Jump 73% - marketscreener.com
Fennec Pharmaceuticals (NASDAQ:FENC) Q1 Beat Overshadowed by Surging Costs - ChartMill
Fennec Pharmaceuticals stock rises 3% on beating EPS, revenue estimates By Investing.com - Investing.com South Africa
Fennec Pharmaceuticals stock rises 3% on beating EPS, revenue estimates - Investing.com India
FENNEC PHARMACEUTICALS ($FENC) Releases Q1 2026 Earnings - Quiver Quantitative
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Fennec Pharmaceuticals Q1 sales rise 73% on PEDMARK demand - TradingView
Fennec Pharma Achieved First Quarter 2026 Total Net Revenues of US$15.1 Million, Up 73% Year Over Year - marketscreener.com
Fennec Pharmaceuticals Inc (FENC) Q1 2026 Earnings Call Highlights: Record Sales Surge and ... By GuruFocus - Investing.com Canada
Fennec Pharmaceuticals (FENC) director exercises 14,344 options and sells shares for tax - Stock Titan
Fennec Pharmaceuticals Inc expected to post a loss of 1 cent a shareEarnings Preview - TradingView
Fennec Pharmaceuticals Inc Stock (FENC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fennec Pharmaceuticals Inc Stock (FENC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RALLIS CHRIS A | Director |
May 11 '26 |
Sale |
7.04 |
8,346 |
58,756 |
63,077 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):